Mycosis fungoides and Sézary syndrome: focus on the current treatment scenario
Open Access
- 1 July 2021
- journal article
- review article
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 96 (4) , 458-471
Abstract
No abstract availableKeywords
This publication has 54 references indexed in Scilit:
- Prolonged survival with the early use of a novel extracorporeal photopheresis regimen in patients with Sézary syndromeBlood, 2019
- Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trialThe Lancet Oncology, 2018
- Retinoic acid receptor agonist as monotherapy for early-stage mycosis fungoides: does it work?Journal of Dermatological Treatment, 2018
- The Use of Interferons in the Treatment of Cutaneous T-Cell LymphomaDermatologic Clinics, 2015
- Modern Radiation Therapy for Primary Cutaneous Lymphomas: Field and Dose Guidelines From the International Lymphoma Radiation Oncology GroupInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2015
- Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphomaLeukemia & Lymphoma, 2015
- Low-dose total skin electron beam therapy as an effective modality to reduce disease burden in patients with mycosis fungoides: Results of a pooled analysis from 3 phase-II clinical trialsJournal of the American Academy of Dermatology, 2015
- Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell LymphomaJournal of Clinical Oncology, 2010
- Low-dose intermittent alemtuzumab in the treatment of Sezary syndrome: clinical and immunologic findings in 14 patientsHaematologica, 2007
- Long-term follow-up in 51 patients with mycosis fungoides and Sézary syndrome treated by interferon-alfaBritish Journal of Dermatology, 1999